Skip to main content
Premium Trial:

Request an Annual Quote

TimeLogic Partners with Bielefeld University to Accelerate Sequence Comparison Algorithms


TimeLogic, a division of Active Motif, said this week that it is partnering with Bielefeld University's Center for Biotechnology to build faster versions of sequence comparison algorithms that will run on its field programmable gate array-based DeCypher biocomputing system.

Alexander Goesmann, executive director of the bioinformatics resource facility at CeBiTec, said that the center will provide validation and benchmarking for a new implementation of Blast that TimeLogic plans to release next year (BI 11/4/2011) as well as a next-generation mapping tool that the company is developing.

This agreement builds on an existing relationship between the two groups. In September, CeBiTec purchased a DeCypher system to support research efforts aimed at discovering new functions of genes and proteins (BI 9/16/2011).

Goesmann said this week that the CeBiTec team has so far integrated TimeLogic's Tera-Blast into its GenDB genome annotation system, "which has relieved the enormous pressure on our sizeable compute cluster."

He added that the CeBiTec researchers are "working on a new platform for metagenomics that will rely heavily on the TimeLogic system.”

In a statement, Ted DeFrank, Active Motif's president, said that his firm was "investing heavily" in its TimeLogic division because of advances in next-generation sequencing that have led to new opportunities for the company.

He added that "working with CeBiTec affords us a great opportunity to strengthen our position" in the market.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.